108729001317022223.pdf (666.55 kB)
Download file

Specific Inhibition of Estrogen Receptor Alpha Function by Antisense Oligodeoxyribonucleotides

Download (666.55 kB)
journal contribution
posted on 19.11.2007, 15:28 by Anthony H. Taylor, J. H. Pringle, Stephen C. Bell, Farook Al-Azzawi
We have tested the effect of a range of antisense oligodeoxyribonucleotides (ODN) directed against the human estrogen receptor alpha (ERα) on ERα protein expression and function. Antisense ERα ODN transfected into the ERα-positive human breast carcinoma cell line MCF7-K2 showed variable responses dependent on the oligo used. The most active antisense ODN (oligo 7) decreased the levels of ERα protein by 61% as measured by Western blot analysis. Exogenous 17β-estradiol (17β-E2), but not 17α-E2, augmented this effect, with a threshold effect at 10-8 M 17β-E2. The inhibitory effect of antisense ERα oligo 7 was confirmed by measurement of functional ERα protein. 3H-17β-E2 binding to MCF7 cell extracts was inhibited to approximately 40% of control values in the presence of oligo 7. Antisense-transfected MCF7-K2 cell cultures produced a further 30% binding reduction in the presence of exogenous 17β-E2. An inhibitory effect on 17β-E2-dependent cell function was confirmed by the demonstration that ERα oligo 7-transfected MCF7-K2 cells failed to exhibit 17β-E2-stimulated cell proliferation. Exogenous 17β-E2 enhanced the inhibitory effect of the antisense ODN by increasing ODN transfection efficiency but without ERα catabolism via the proteosomal pathway, suggesting an effect of 17β-E2 on the plasma membrane and the existence of different ERα degradation pathways in the MCF7-K2 cell subclone. As 17β-E2 had no effect on ER α protein degradation, we conclude that the observed reduction of ER α protein levels is due solely to the presence of the antisense ERα ODN. Antisense ERα ODN molecules, therefore, may form the basis of effective therapies against ERα-dependent malignancies.



Antisense and Nucleic Acid Drug Development, 2001, 11 (4), pp.219-231


VoR (Version of Record)

Published in

Antisense and Nucleic Acid Drug Development


Mary Ann Liebert, Inc., on behalf of the Oligonucleotide Therapeutics Society (OTS)





Copyright date


Available date


Publisher version




Usage metrics